Dyne Therapeutics gets grant for patent granted for method of reducing DMPK expression in muscle

2d ago, source: Pharmaceutical Technology

Reduce DMPK expression in muscle cells with Dyne Therapeutics' patented method using an anti-transferrin receptor antibody linked to an oligonucleotide. Learn more about this potential treatment for ...

Dyne Therapeutics Inc Ordinary Shares

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Dyne Therapeutics Announces CEO Transition

1mon ago, source: Business Insider

March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living ...

Dyne Therapeutics Inc (DYN) Shares Down Despite Recent Market Volatility

6d ago, source: newsheater

The stock of Dyne Therapeutics Inc (NASDAQ: DYN) has decreased by -4.71 when compared to last closing price of 24.82. Despite this, the company has experienced a -13.62% fall in its stock price over ...

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

28d ago, source: WIVB-TV

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium

29d ago, source: Yahoo Finance

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ...

Dyne Therapeutics Announces CEO Transition

1mon ago, source: Stockhouse

March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with ...

Dyne Therapeutics, Inc.: Dyne Therapeutics Announces CEO Transition

1mon ago, source: Finanznachrichten

March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living ...